While the coronavirus has impacted millions of Americans across the United States, it has hit the elderly population particularly hard. In fact, more than 40 percent of coronavirus deaths in the U.S. have been linked to long-term care facilities, according to a New York Times survey. In an effort to bring those numbers down, pharmaceutical company Eli Lilly, in partnership with the National Institutes of Health (NIH), has just launched a late-stage antibody treatment trial focusing on residents and staff at nursing homes.
"COVID-19 has had a devastating impact on nursing home residents," Lilly's chief scientific officer Daniel Skovronsky said in a statement. "We're working as fast as we can to create medicines that might stop the spread of the virus to these vulnerable individuals."
The trial is expected to enroll up to 2,400 participants who live or work at a facility and have recently been diagnosed with the disease. The trial will evaluate the safety and success of using LY-CoV555, a potent, neutralizing antibody that works against the spike protein of the novel coronavirus. The trial will look at whether a single dose of the antibody treatment reduces the rate of infection over four weeks as well as symptoms over eight weeks.
"The importance of these kinds of therapies for people like the elderly or immunocompromised is that they can provide the hope and the safety net that these people really need right now," said Andrew Adams, vice president of new therapeutic modalities & COVID-19 research at Eli Lilly, who is overseeing the trial. "I think people in those populations are really desperate and looking for something to help with the coronavirus."
Eli Lilly is taking its trial on the road with customized mobile research units that can travel directly to areas that are experiencing outbreaks.
"This is an interesting solution, to bring the medicine to these vulnerable patients," said Adams. "This lets us be flexible and move these trials around the country, tracking these trials as we come across them."
Adams said he is hoping Eli Lilly will have results on the efficacy of these antibodies in the fourth quarter of this year. Even if successful, though, he says research for a vaccine needs to continue.
"These have to be thought of as more of a bridge, where a vaccine provides long-term protection in terms of years of immunity, where we will provide hopefully in the range of months with these types of treatments. We hope this to be a short-term bridge to the long-term effective vaccination," he said.
The United Nations COP26 climate talks are scheduled for October 31 to November 12 in Glasgow, Scotland. Heads of state will be joined by private sector leaders to once again discuss the shrinking window of time left to take action against global temperature rise. Barbara Humpton, CEO of focused technology company Siemens U.S., is also attending and spoke to Cheddar about what she hopes to see during the conference for both the public and private spheres. "What we are really urging is that there are large commitments made in Glasgow and that we really commit to this next decade of action," she said.
Voyager, Nanoracks, and Lockheed Martin are all teaming up to develop the first-ever free-flying commercial space station with room for a crew of four astronauts. The private companies are joining forces as part of NASA’s greater mission to retire the International Space Station by the year 2030. The low-earth orbit space station will be called "Starlab," and is planned to achieve operational capability by 2027. Lisa Callahan, Vice President and General Manager of Commercial Civil Space at Lockheed Martin, and Matthew J. Kuta, President and Chief Operating Officer of Voyager Space, joined Cheddar’s Opening Bell.
Jill and Carlo cover the latest developments in the Alec Baldwin prop gun shooting, when vaccines for kids as young as 5 should be approved, new reporting on Facebook and more.
Middle school students from across the country battled it out for a chance at being crowned 'America's Top Scientist.' Each applicant had to submit a video to compete in the '3M Young Scientist Challenge' and describe a unique solution to an everyday problem for the chance to win $25,000. 10 finalists were chosen and after a two-day virtual competition, one walked away with the title. 14-year-old Sarah Park won the award, she joins Cheddar News to talk about her invention Spark Care+.
NIAID Director Dr. Anthony Fauci has stated that recipients of the single-dose Johnson & Johnson COVID-19 vaccine should have gotten two doses, to begin with. An FDA panel had recently recommended that J&J boosters be made available for everyone who received the single dose.
Richard Branson’s Virgin Galactic is delaying its launch date for commercial space flights to Q4 of 2022 following a rescheduled test flight. Shares for the aerospace company fell on the news.
The NIH released findings of a study that say recipients of the Johnson & Johnson COVID-19 vaccine may benefit from getting Pfizer or Moderna boosters as the antibody levels from those shots were seen as more robust than from a Johnson & Johnson booster.
"Star Trek" actor William Shatner's voice broke with emotion as he recounted his trip into space on the Blue Origin New Shepard rocket to Jeff Bezos on October 13, 2021.
